News
Hims & Hers Rallies After Novo Nordisk Deal on Wegovy
In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering will launch this week, the company said. Shares of Hims & Hers soared 30% to $36.94 premarket, but remain below February peaks. Novo Nordisk rose 4% to $65.10.
In fact, until just recently these products have been on the U.S ... the same manner as these market-leading products.
Novo Nordisk's booming obesity drugs & diabetes portfolio make it a top growth play. Click here to read an analysis of NVO ...
The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...
A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.
Zacks Investment Research on MSN1d
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?Novo Nordisk NVO is expected to beat estimates when it reports its first-quarter 2025 results before the opening bell on May ...
Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback